NIAID Site Search

NIAID studies Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome, a rare genetic disease of the immune system.

Last Reviewed: April 15, 2019

Nico Contreras, Ph.D., of University of Arizona, F31 sample application

Last Reviewed: March 31, 2025

Lenette Lu, M.D., Ph.D., of the Massachusetts General Hospital K08 sample application

Last Reviewed: March 31, 2025

Information about Father of the NIH, Dr. Kinyoun, and his role in fighting the plague in San Francisco.

Last Reviewed: August 28, 2012

Immunology Interest Group (IIG) Newsletter November 2024

Last Reviewed: December 4, 2024

Sample application from David Al-Adra MD, Ph.D., for NIH standard independent research project grant (K08).

Last Reviewed: September 13, 2024

National Institutes of Health // Food and Drug Administration // Immunology Interest Group

Last Reviewed: February 9, 2024

Biology of spirochetes Bacterial regulatory RNAs and proteins Bacterial transcriptomics Determinants of Borrelia burgdorferi tick and mammalian infection Molecular Genetics of Treponema pallidum

Last Reviewed: February 19, 2025

Jordan Report: Accelerated Development of Vaccines (2012) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2012

Sample application from Samantha Lynne Schwartz, Ph.D., for National Research Service Award (NRSA) individual fellowship (F31) grants.

Last Reviewed: March 16, 2023

Expert articles from Jordan Report: Accelerated Development of Vaccines (2012) from NIAID

Last Reviewed: December 31, 2012

Sample application from Artem Domashevskiy, Ph.D., for Research Enhancement Award (R15) grant.

Last Reviewed: November 29, 2022

Jordan Report: Accelerated Development of Vaccines (2007) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: August 6, 2019

Dr. Barry received his Ph.D. in organic and bio-organic chemistry in 1989 from Cornell University. He joined NIAID following postdoctoral research at Johns Hopkins University. In 1998, he was tenured as chief of the TBRS. Dr. Barry is a member of several editorial boards, has authored more than 300 research publications in tuberculosis, and is the most cited researcher in the field, according to ScienceWatch.com.

Last Reviewed: January 12, 2024

Sample application from Vernita Gordon, Ph.D., for NIH standard independent research project grant (R01).

Last Reviewed: January 25, 2023

Jordan Report: Accelerated Development of Vaccines (2002) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2002

This document summarizes complexities of genetic determinants that lead to antigenic differences among pandemic GII.4 noroviruses.

Last Reviewed: July 6, 2021

The Adams Research Group uses molecular and cellular techniques to manipulate spirochetes, sequence bacterial transcriptomes, characterize cellular processes, map regulatory networks, and study spirochetes during infection.

Last Reviewed: December 17, 2024

Eli Boritz, M.D., Ph.D., is the Chief of Virus Persistence and Dynamics Section (VPDS). The goal of the VPDS is to help develop means of targeting virus reservoirs and reducing disease progression in people living with HIV. One path toward this goal is to clarify the fundamental biology of HIV persistence during antiretroviral therapy (ART). Motivated by the genetic and functional diversity within key cellular reservoirs for the virus, we are developing high-throughput methods for characterizing large numbers of single cells and viruses in great detail.

Last Reviewed: January 6, 2023

Sample application from Rahul Raghavan, Ph.D., for Research Enhancement Award (R15) grant.

Last Reviewed: November 28, 2022

Last Reviewed: May 5, 2022

The Virus Persistence and Dynamics Section (VPDS) works to understand the persistence of HIV and other viruses in vivo by developing and applying advanced sequencing and other technologies.

Last Reviewed: September 26, 2022

TBRS is a multidisciplinary group composed of chemists, microbiologists, veterinarians, imaging scientists, and clinicians with a shared objective of improving chemotherapy for tuberculosis (TB) patients. Projects span chemical biology, medicinal chemistry, host-pathogen interactions, animal models of experimental chemotherapy, and experimental medicine clinical studies in TB patients.

Last Reviewed: March 11, 2025

This page covers NIAID Human Subjects Resources. Table of Contents General Human Subjects Planning a Human Subjects Application Planning an Investigator-Initiated Clinical Trial Human Subjects Documentation Human Subjects Research Plan Data Sharing Plan Human Subjects Protocol Data and Safety Monitoring Plan Phase III Clinical Trials Target Study Enrollment IND or IDE Requirements rDNA

Last Reviewed: August 30, 2019

NBBTP/IRTA Fellows are trained specifically to support high containment research environments. Upon graduating from the program, NBBTP/IRTA alumni begin work as biorisk professionals with the knowledge and skills necessary to meet the scientific, regulatory, biocontainment, biosafety, engineering, communications, management, and public relations challenges associated with the conduct of research

Last Reviewed: January 21, 2025